Dermavant Sciences has shared positive late-stage results for its plaque psoriasis-approved Vtama (tapinarof) cream in adults and children as young as two years old with atopic dermatitis.

More commonly referred to as eczema, atopic dermatitis is one of the most common inflammatory skin diseases, affecting over 26 million people in the US alone and up to 10% of adults and 20% of children worldwide.

According to results from the identically designed vehicle-controlled ADORING 1 and ADORING 2 trials presented at the American Academy of Dermatology (AAD) Annual Meeting, Vtama cream demonstrated statistically significant efficacy in adults and children with atopic dermatitis across a range of skin tones.

In ADORING 1 and ADORING 2, 47% and 43.1% of Black or African American patients, respectively, achieved the shared primary endpoint of a Validated Investigator Global Assessment for Atopic Dermatitis score of zero (clear) or one (almost clear) and at least a two-grade improvement from baseline at week eight.

This was achieved by 39.5% and 48.9% of Asian patients and 49.4% and 52.1% of white patients in ADORING 1 and ADORING 2, respectively.

Benefits were also seen across key secondary endpoints, including 75% or more improvement on the EASI test, which is used to measure the extent and severity of the condition.

“The data on treatment of patients with skin of colour presented today at the AAD annual meeting is extremely promising, as it highlights Vtama cream’s ability to achieve consistent and strong efficacy across all racial groups,” said Dermavant’s chief medical officer, Philip Brown.

He continued: “Based on the results we have reported thus far, we are enthusiastic about Vtama cream’s potential, and if approved by the US Food and Drug Administration for atopic dermatitis, we believe that Vtama cream will make a meaningful difference for the diverse patient population suffering with atopic dermatitis.”